The short-term effects of low-dose estrogen and micronized progesterone on bone turnover markers and serum lipid profiles in postmenopausal women.
- Author:
Ki Won OH
1
;
Eun Joo YUN
;
Eun Sook OH
;
Seong Kyu LEE
;
Sang Woo KIM
;
Duk Chul LEE
;
Sung Il ROH
;
Won Young LEE
;
Ki Hyun BAEK
;
Moo Il KANG
Author Information
1. Department of Internal Medicine, Miz Medi Hospital, Seoul, Korea. okwendo@yahoo.co.kr
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Low-dose Estrogen;
Micronized Progesterone
- MeSH:
Alkaline Phosphatase;
Breast;
Breast Neoplasms;
Cholesterol, HDL;
Cholesterol, LDL;
Estrogens*;
Estrogens, Conjugated (USP);
Female;
Hemorrhage;
Hormone Replacement Therapy;
Humans;
Lipid Metabolism;
Mastodynia;
Medroxyprogesterone Acetate;
Osteocalcin;
Progesterone*;
Triglycerides;
Weight Gain
- From:Korean Journal of Medicine
2003;64(2):178-187
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Hormone replacement therapy in postmenopausal women is widely used for the relief of menopausal symptoms and the prevention of bone loss. But, it has been reported that many women discontinue hormone replacement therapy within early period, because the women suffer from breast pain, bleeding and weight gain. Also, further adverse influence of hormone replacement therapy on cardiovascular risk and breast cancer has been suggested. There are many controversies due to conflicting data of that. Recent studies suggest that low-dose estrogen provide bone benefits and micronized progesterone have favorable effects on lipid metabolism and breast density. This clinical trial evaluated the short-term effects of low-dose estrogen and micronized progesterone on bone turnover markers and serum lipid profiles in postmenopausal women. METHODS: This was a 12-week study in which 90 postmenopausal women received hormone replacement therapy. Participants were assigned in equal numbers to the following groups: (1) daily treatment with 0.625 mg conjugated equine estrogens (CEE) with medroxyprogesterone acetate MPA 2.5 mg to 5 mg, daily or cyclically; (2) daily treatment with 0.625 mg CEE with micronized progesterone (MP) 100 mg to 200 mg, daily or cyclically; (3) daily treatment with 0.3 mg CEE with MP 100 mg to 200 mg, daily or cyclically. Changes in bone turnover markers and serum lipid profiles were assessed. RESULTS: At 12-week, all treatment groups significantly improved bone turnover markers and serum lipid profiles, specifically serum alkaline phosphatase, serum osteocalcin, urine deoxypyridinoline and serum high density lipoprotein cholesterol level. CEE 0.625/MPA and CEE 0.625/MP significantly decreased serum low density lipoprotein cholesterol level. CEE 0.625/MPA significantly increased serum triglyceride level. CEE 0.625/MPA produced greater decreases in serum alkaline phosphatase level than CEE 0.625/MP and CEE 0.3/MP. CEE 0.625/MP produced greater increases in serum high density lipoprotein cholesterol level than CEE 0.625/MPA. CEE 0.625/MPA produced greater increase in serum triglyceride level than CEE 0.3/MP. CONCLUSION: Low-dose estrogen and MP generally improved bone turnover markers and serum lipid profiles. But, MP produced lesser favorable effects on a part of bone turnover markers. MP produced significantly greater increases in serum high density lipoprotein cholesterol than that of MPA. And Low-dose estrogen produced significantly lesser increases in triglyceride than that of conventional dose.
